CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized genome engineering, offering a precise and efficient gene editing method for making targeted changes to DNA sequences within organisms. This technology holds immense potential for advancing human health by facilitating the development of novel therapeutics and treatments, especially in gene therapy and cell therapy. Additionally, its application in creating cellular models to study human diseases more accurately aids in drug discovery and development.


MAD7, also known as ErCas12a, is a nuclease analogous to Cas12a, distinguished by its effective cleavage of target DNA following 5’-YTTN-3’ protospacer adjacent motifs. This enzyme expands the repertoire of options for CRISPR-based genome editing. Notably, MAD7 boasts a well-defined patent status, offering clarity and legal assurance concerning its intellectual property rights. Recognizing its technological and intellectual property merits, Allele has allocated resources to establish a gene editing service platform centered around MAD7. This endeavor has been facilitated by a broad licensing agreement that authorizes the utilization of MAD7 for developmental activities.

Related Pages
GMP Genome Editing Gene Editing in iPSCs